Globe Newswire
BELGRADE, Mont., May 20, 2024 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today responded to questions from various constituencies as a result of recent politically-motivated attacks on its business in certain media outlets.
In recent weeks, candidates for political office and their allied political... (continue reading...)
SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events.
Company advances SNK01 into Phase 2 in moderate Alzheimer’s disease; first patient enrolled in Phase 2 expected in Q2 2024.
SANTA ANA, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology... (continue reading...)
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase... (continue reading...)
WILMINGTON, Del., May 20, 2024 (GLOBE NEWSWIRE) -- The law firm of Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders, is investigating potential securities violations and breach of fiduciary duty claims against Blueprint Medicines Corporation (NASDAQ: BPMC) (“Blueprint Medicines” or the “Company”).
If you currently own shares of Blueprint Medicines and want to receive additional information and protect... (continue reading...)
Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions
The eAArly DETECT results demonstrated that within the advanced precancerous lesion patients, 100% of those patients with high grade dysplasia were detected
The Company’s mission is to transform current colorectal cancer screening practices, and ultimately to reduce cancer mortality rates worldwide by shifting from cancer detection to cancer... (continue reading...)
More Globe Newswire
View Older Stories-
Seacoast Bank Welcomes Tony Coley as Regional President, South Florida
-
Prosper Gold Provides Update on Option Agreement to Acquire the Kaza and Northstar Properties
-
Infinera to Participate in J.P. Morgan’s 2024 Global Technology, Media and Communications Conference
-
APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 (florzolotau) for the Diagnosis of Progressive Supranuclear Palsy
-
Zehnder’s of Frankenmuth Announces Future Plans
-
Sow Good to Ring the Nasdaq Opening Bell Today, May 20, 2024
-
Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome
-
NV5 Strengthens Subscription-Based Services with Acquisition of myBIMteam
-
CervoMed to Appoint William Elder as Chief Financial Officer
-
GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors
-
Infinera Names Regan MacPherson Chief Legal Officer and Corporate Secretary
-
ABM Recognized as One of the Best Places to Work in Healthcare
-
PetMed Express, Inc. Announces Appointment of Justin Mennen to Board of Directors
-
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Volta Medical presents results from the first transatlantic randomized controlled trial comparing AI-assisted ablation procedure with the conventional treatment for persistent atrial fibrillation pati
-
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
-
Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention
-
Telesign Recognized as the Best Fraud Protection Company by the Cybersecurity Excellence Awards
-
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
-
Genius Group Announces Exercise of Warrants for $3.8 Million Gross Proceeds
-
Kairous Acquisition Corp. Limited Announces Additional Contribution to Trust Account to Extend Period to Consummate Business Combination
-
InnovAge Welcomes John Koehn as Senior Vice President of External Affairs
-
Scorpius Holdings Announces Major Expansion in San Antonio with New State-of-the-Art Storage and Testing Facility
-
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
-
PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot Ulcers
-
“Breaking Points” Podcast Launches on Rumble
-
RYVYL Extends its Obligation to Repay Convertible Note to April 2026
-
Coca-Cola Consolidated Announces Commencement of Tender Offer to Purchase up to $2.0 Billion in Value of its Common Stock
-
Discover the Newest Way to Create Punchy, Flavorful Beverages
-
Soon You’ll Be Able to Measure and Improve Your Brain Performance, Anytime, Anywhere
-
Dave Cantin Group Introduces First-Ever AI-Powered Data-Mining Software to Accurately Value the Nation’s 18,000+ Franchise Dealerships
-
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
-
authID to Hold Annual Meeting of Stockholders on June 26th
-
Intercept Presents New Sub-Analyses of Phase 3 POISE Data Showcasing the Effect of OCA on Key Liver Biomarkers and Fibrosis in Patients with PBC at Digestive Disease Week® 2024
-
Hopebridge Continues to Grow Autism Therapy Services by Opening Two New Locations in North Carolina
-
STMicroelectronics Announces Status of Common Share Repurchase Program
-
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
-
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
-
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
-
Alliance Trust PLC - Net Asset Value
-
Infrared Sauna Use in UCSF Clinical Trial Shows Promise in Combating Depression
-
Form 8.3 - AXA INVESTMENT MANAGERS: Darktrace plc
-
Form 8.3 - AXA INVESTMENT MANAGERS: Spirent Communications plc
-
Alta Equipment Group Announces Proposed Private Offering of $500 Million of Senior Secured Second Lien Notes
-
Leading Proxy Advisory Firms Recommend Shareholders Vote “FOR” All of Crown Castle’s Director Nominees
-
Agrify Corporation Mutually Agrees to Terminate Plan to Merge with Nature’s Miracle
-
Nexxen Reports Results for the First Quarter Ended March 31, 2024
-
Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders
-
BrightSpring Health Services Announces Onco360® Was Selected as National Pharmacy Partner for OJEMDA™
-
SL Green Realty Corp. Announces Common Stock Dividend